BIRC3 and hepatocellular carcinoma: In addition, BIRC3 is reported to improve the prognostication system in Chronic Lymphocytic Leukemia (Alhourani et al., 2016) and hepatocellular carcinoma patients undergoing curative resection (Fu et al., 2019).